Canine IL-13 receptor alpha-1 subunit nucleic acid molecules
View Patent ↗The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13Rα) proteins, particularly canine interleuken receptor alpha 1 (IL-13Rα1) and canine interleuken receptor alpha 2 (IL-13Rα2) proteins. Also included are canine IgG and IL-13Rα proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors. Also included are kits containing said molecules or chimera thereof, including their use to evaluate and regulate an immune response in an animal.
1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
(a) a nucleic acid sequence encoding a protein comprising an amino acid sequence at least 95% identical to SEQ ID NO:50; wherein said protein binds canine IL-13;
(b) a nucleic acid sequence encoding a protein comprising at least 100 contiguous amino acids identical in sequence to 100 contiguous amino acids from SEQ ID NO:50; wherein said protein binds canine IL-13; and
(c) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a) or (b).
2. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid sequence encodes a protein comprising SEQ ID NO:50.
3. The isolated nucleic acid molecule of claim 1 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.
4. A recombinant molecule comprising the nucleic acid molecule of claim 1 operatively linked to a transcription control sequence.
5. A recombinant virus comprising the isolated nucleic acid molecule of claim 1 .
6. A recombinant cell comprising the isolated nucleic acid molecule of claim 1 .
7. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:
(a) a nucleic acid sequence comprising at least 300 contiguous nucleotides identical in sequence to 300 contiguous nucleotides from SEQ ID NO:49 or SEQ ID NO:52, wherein said nucleic acid sequence encodes a protein that binds canine IL-13;
(b) a nucleic acid sequence at least 95% identical to SEQ ID NO:49 or SEQ ID NO:52, wherein said nucleic acid sequence encodes a protein that binds canine IL-13; and,
(c) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a) or (b).
8. The isolated nucleic acid molecule of claim 7 , wherein said nucleic acid sequence is selected from the group consisting of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.
9. A recombinant molecule comprising the nucleic acid molecule of claim 7 operatively linked to a transcription control sequence.
10. A recombinant virus comprising the isolated nucleic acid molecule of claim 7 .
11. A recombinant cell comprising the isolated nucleic acid molecule of claim 7 .
12. An isolated nucleic acid molecule encoding a fusion protein comprising a carrier protein domain fused to a second protein domain selected from the group consisting of:
(a) a protein domain comprising an amino acid sequence at least 95% identical in sequence to SEQ ID NO:50, wherein said protein binds canine IL-13; and
(b) a protein domain comprising at least 100 contiguous amino acids identical in sequence to at least 100 contiguous amino acids from SEQ ID NO:50, wherein said protein binds canine IL-13.
13. The isolated nucleic acid molecule of claim 12 , wherein said encoded carrier protein domain is an immunoglobulin Fc region.
14. The isolated nucleic acid molecule of claim 12 , wherein said encoded carrier protein domain is a canine immunoglobulin IgG Fc region.
15. The isolated nucleic acid molecule of claim 12 , wherein said second protein domain comprises SEQ ID NO:50.
16. A fusion protein comprising a carrier protein domain fused to a second protein domain selected from the group consisting of:
(a) a protein domain comprising an amino acid sequence at least 95% identical in sequence to SEQ ID NO:50, wherein said protein binds canine IL-13; and
(b) a protein domain comprising at least 100 contiguous amino acids identical in sequence to at least 100 contiguous amino acids from SEQ ID NO:50, wherein said protein binds canine IL-13.
17. The fusion protein of claim 16 , wherein said second protein domain comprises SEQ ID NO:50.
18. An isolated nucleic acid molecule, wherein said isolated nucleic acid molecule consists of at least 100 contiguous nucleotides from a nucleic acid sequence selected from the group consisting of (a) a nucleic acid sequence that encodes SEQ ID NO:50, and (b) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).
19. The isolated nucleic acid molecule of claim 18 , wherein said nucleic acid molecule consists of a nucleic acid sequence selected from the group consisting of (a) a nucleic acid sequence encoding SEQ ID NO:50, and (b) a nucleic acid sequence fully complementary to the nucleic acid sequence of (a).
20. The isolated nucleic acid molecule of claim 18 , wherein said nucleic acid molecule consists of a nucleic acid sequence selected from the group consisting of SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.